Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The ...

Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...

After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

Appeals court upholds J&J win blocking Mylan's generic version of schizophrenia drug Invega Trinza, protecting patent for ...

DBV Technologies could get $306M for peanut allergy patch; Eisai sells Pariet rights in China; Palatin reports UC trial data; ...

BioNTech's BNT327 shows promising survival data in lung cancer trial, with 72.7% of patients surviving one year, ...

Alumis and Acelyrin had merger talks in 2023 before current deal. SEC filing shows earlier reverse merger attempt, followed ...

Merck KGaA pays $85M for global rights to Abbisko's pimicotinib, a CSF-1R inhibitor for TGCT that competes with Daiichi ...

Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision.

Novo Nordisk partners with Lexicon Pharmaceuticals for obesity drug LX9851 in deal worth up to $1B, including $75M upfront ...

HHS announces major downsizing, cutting 20,000 jobs total across FDA, CDC, and NIH. New Administration for Healthy America to ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...